{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:57:23Z","timestamp":1793422643285,"version":"4.5.0"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2020,4,1]]},"DOI":"10.1001\/jamaoncol.2019.5570","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T19:12:02Z","timestamp":1577992322000},"page":"519","source":"Crossref","is-referenced-by-count":409,"title":["Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo"],"prefix":"10.1001","volume":"6","author":[{"given":"Alexander M. M.","family":"Eggermont","sequence":"first","affiliation":[{"name":"Gustave Roussy Cancer Campus Grand Paris, Universite Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Kicinski","sequence":"additional","affiliation":[{"name":"European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian U.","family":"Blank","sequence":"additional","affiliation":[{"name":"Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mandala","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, University of Sydney and Mater and Royal North Shore Hospitals, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Atkinson","sequence":"additional","affiliation":[{"name":"Princess Alexandra Hospital, University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Dalle","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon Cancer Institute, Lyon University, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Haydon","sequence":"additional","affiliation":[{"name":"Alfred Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Khattak","sequence":"additional","affiliation":[{"name":"Fiona Stanley Hospital, University of Western Australia, Perth, Washington, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[{"name":"Westmead and Blacktown Hospitals, Melanoma Institute Australia and the University of Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Larkin","sequence":"additional","affiliation":[{"name":"Royal Marsden Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Puig","sequence":"additional","affiliation":[{"name":"Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[{"name":"Maria Sklodowska-Curie Institute Cancer Centre and Institute of Oncology, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[{"name":"University Hospital Essen, Essen, Germany"},{"name":"Germany and German Cancer Consortium of Translational Cancer Research, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutger","family":"Koornstra","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center Nijmegen, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonel","family":"Hernandez-Aya","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Di Giacomo","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonsus J. M.","family":"van den Eertwegh","sequence":"additional","affiliation":[{"name":"Vrije Universiteit Medical Center Amsterdam, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Grob","sequence":"additional","affiliation":[{"name":"Hopital de la Timone, Aix-Marseille University, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[{"name":"Skin Cancer Center, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahima","family":"Jamal","sequence":"additional","affiliation":[{"name":"Centre de Recherche, Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Lorigan","sequence":"additional","affiliation":[{"name":"Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Krepler","sequence":"additional","affiliation":[{"name":"Merck & Co, Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nageatte","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Merck & Co, Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Marreaud","sequence":"additional","affiliation":[{"name":"European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"van Akkooi","sequence":"additional","affiliation":[{"name":"Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[{"name":"Gustave Roussy Cancer Campus Grand Paris, Universite Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Suciu","sequence":"additional","affiliation":[{"name":"European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9919","key":"coi190101r1","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S0140-6736(13)60802-8","article-title":"Cutaneous melanoma.","volume":"383","author":"Eggermont","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"coi190101r2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti\u2013CTLA-4 and anti\u2013PD-1 antibodies alone and in combination.","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"coi190101r3","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti\u2013PD-1 therapy.","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"coi190101r4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti\u2013PD-1 therapy.","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"issue":"7","key":"coi190101r5","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1056\/NEJMe058307","article-title":"Autoimmunity and immunotherapy for cancer.","volume":"354","author":"Koon","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"coi190101r6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s40425-017-0307-5","article-title":"Improved survival and tumor control with interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM registry.","volume":"5","author":"Curti","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"7","key":"coi190101r7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa053007","article-title":"Prognostic significance of autoimmunity during treatment of melanoma with interferon.","volume":"354","author":"Gogas","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"coi190101r8","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/jnci\/djp132","article-title":"Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.","volume":"101","author":"Bouwhuis","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"coi190101r9","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2009.24.6264","article-title":"Phase III trial comparing adjuvant treatment with pegylated interferon alfa-2b versus observation: prognostic significance of autoantibodies\u2014EORTC 18991.","volume":"28","author":"Bouwhuis","year":"2010","journal-title":"J Clin Oncol"},{"issue":"30","key":"coi190101r10","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody.","volume":"37","author":"Maher","year":"2019","journal-title":"J Clin Oncol"},{"issue":"25","key":"coi190101r11","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi190101r12","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes.","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"coi190101r13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00432-018-2819-x","article-title":"Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.","volume":"145","author":"Indini","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"coi190101r14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non\u2013small-cell lung cancer.","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"coi190101r15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00432-018-2805-3","article-title":"Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.","volume":"145","author":"Ricciuti","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"24","key":"coi190101r16","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1200\/JCO.2008.16.1000","article-title":"Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables.","volume":"26","author":"Anderson","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi190101r17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis.","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"issue":"19","key":"coi190101r18","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma.","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"coi190101r20","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"coi190101r24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","article-title":"Survival of patients with advanced metastatic melanoma: the impact of novel therapies\u2014update 2017.","volume":"83","author":"Ugurel","year":"2017","journal-title":"Eur J Cancer"},{"issue":"19","key":"coi190101r25","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy.","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"coi190101r26","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma.","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"coi190101r27","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1002\/(ISSN)1097-0215","article-title":"Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.","volume":"121","author":"Satzger","year":"2007","journal-title":"Int J Cancer"},{"issue":"2","key":"coi190101r28","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2340\/00015555-3061","article-title":"Induced vitiligo due to talimogene laherparepvec injection for metastatic melanoma associated with long-term complete response.","volume":"99","author":"Iglesias","year":"2019","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"coi190101r29","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/CCO.0b013e328341edff","article-title":"Autoimmunity and treatment outcome in melanoma.","volume":"23","author":"Bouwhuis","year":"2011","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"coi190101r30","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/annonc\/mdx818","article-title":"Immune-related adverse events of immune checkpoint inhibitors and the impact of sex\u2014what we know and what we need to learn.","volume":"29","author":"\u00d6zdemir","year":"2018","journal-title":"Ann Oncol"},{"issue":"28","key":"coi190101r31","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death\u2013ligand 1 blockade in patients with non\u2013small-cell lung cancer.","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"coi190101r32","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/j.jtho.2018.06.004","article-title":"Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab.","volume":"13","author":"Scott","year":"2018","journal-title":"J Thorac Oncol"},{"key":"coi190101r19","volume-title":"AJCC Cancer Staging Manual","author":"Edge","year":"2009","edition":"7th ed"},{"key":"coi190101r22","volume-title":"Survival Analysis. Techniques for Censored and Truncated Data","author":"Klein","year":"1997"},{"key":"coi190101r23","doi-asserted-by":"crossref","DOI":"10.1201\/b18695","volume-title":"Data Analysis With Competing Risks and Intermediate States","author":"Geskus","year":"2015"},{"key":"coi190101r21","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6 (R1). https:\/\/apps.who.int\/medicinedocs\/documents\/s22154en\/s22154en.pdf. Published June 10, 1996. Accessed November 14, 2019."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2757843\/jamaoncology_eggermont_2020_oi_190101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T15:15:26Z","timestamp":1586445326000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2757843"}},"subtitle":["A Secondary Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2019.5570","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,1]]}}}